Relationship between Thyroid Hormone Levels and Non-alcoholic Fatty Liver Disease in Euthyroid Population

doi:10.12114/j.issn.1007-9572.2019.00.494

Abstract

Abstract: Background　The incidence of non-alcoholic fatty liver disease（NAFLD） is rising year by year，and is increasingly occurring in younger people.Moreover，its occurrence is related to the components of metabolic syndrome，while hypothyroidism is closely related to the occurrence of metabolic syndrome.Currently，the relationship between thyroid hormone levels and NAFLD in people with normal thyroid function in studies has not been determined.Objective　To investigate the relationship between thyroid hormone levels and NAFLD in people with normal thyroid function，so as to provide a basis for the prevention and treatment of NAFLD.Methods　From the hospital information system database of the First Affiliated Hospital of China Medical University，15 660 physical examinees with normal thyroid function were enrolled during January 2013 to October 2018.By color Doppler ultrasound examination of the liver，7 095 were found with NAFLD（NAFLD group），and 8 565 without（non-NAFLD group）．The levels of thyroid-stimulating hormone（TSH），free triiodothyroine（FT3） and free thyroxine（FT4） in the two groups were compared.Logistic regression analysis was conducted to explore the changes in prevalence of NAFLD by thyroid hormone level.Stepwise multiple Logistic regression was used to analyze the effect of thyroid hormone level on the prevalence of NAFLD.Results　NAFLD group showed higher mean serum levels of TSH and FT3，and lower mean serum FT4 level compared with non-NAFLD group（P<0.05）．The prevalence of NAFLD increased with the elevation of serum TSH and FT3 levels but reduced with the growth of FT4 level（Ptrend<0.05）．Stepwise multiple regression analysis showed that after excluding the multicollinearity effect of thyroid hormone level，and adjusting for sex，age and other metabolism-related indicators，serum TSH〔OR=1.065，95%CI（1.019，1.113）〕，FT3〔OR=1.175，95%CI（1.078，1.282）〕，and FT4〔OR=0.934，95%CI（0.908，0.961）〕 levels were the influencing factors of NAFLD（P<0.05）．Conclusion　In people with normal thyroid function，higher serum TSH and FT3 levels and lower serum FT4 level are associated with higher risk of NAFLD.To effectively prevent and delay the occurrence and development of NAFLD in this group，health managers should focus on monitoring the changes of TSH，FT3 and FT4 levels.

Key words: Fatty liver, alcoholic；Thyroid hormones；Metabolic syndrome X；Root cause analysis

摘要： 背景　非酒精性脂肪肝（NAFLD）的发病率呈年轻化和逐年增加趋势，其发生与代谢综合征各组分有关，而甲状腺功能减退与代谢综合征的发生密切相关。目前，关于甲状腺功能正常人群中甲状腺激素水平与NAFLD关系的研究尚存在差异。目的　探讨甲状腺功能正常人群中甲状腺激素水平与NAFLD的关系，为NAFLD的防治提供依据。方法　在中国医科大学附属第一医院的医院信息系统（HIS）中选取2013年1月—2018年10月进行健康体检的甲状腺功能正常者15 660例，根据彩超检查结果，分为NAFLD组7 095例和非NAFLD组8 565例。比较两组促甲状腺素（TSH）、游离三碘甲状腺氨酸（FT3）、游离甲状腺素（FT4）水平，采用Logistic回归分析NAFLD患病率随甲状腺激素水平的变化，采用多元逐步Logistic回归分析甲状腺激素水平对NAFLD患病的影响。结果　NAFLD组的血清TSH和FT3水平高于非NAFLD组，血清FT4水平低于非NAFLD组（P<0.05）。NAFLD患病率随血清TSH和FT3水平升高而上升，随血清FT4水平升高而下降（P趋势<0.05）。多元逐步Logistic回归分析结果显示，排除了甲状腺激素水平的共线性影响，调整了性别、年龄及其他代谢相关指标的影响后，血清TSH、FT3、FT4水平是NAFLD患病与否的影响因素〔OR（95%CI）分别为1.065（1.019，1.113）、1.175（1.078，1.282）、0.934（0.908，0.961），P<0.05〕。结论　在甲状腺功能正常的人群中，血清TSH、FT3水平越高，血清FT4水平越低，NAFLD的患病风险越高。健康管理师应重点监测这部分人群的TSH、FT3及FT4水平变化，从而有效预防和延缓NAFLD的发生发展。

关键词: 脂肪肝, 酒精性；甲状腺激素类；代谢综合征X；影响因素分析

LIU Yiting,WANG Wei. Relationship between Thyroid Hormone Levels and Non-alcoholic Fatty Liver Disease in Euthyroid Population　[J]. Chinese General Practice, 2019, 22(25): 3088-3093. DOI: 10.12114/j.issn.1007-9572.2019.00.494.
刘奕婷,王巍. 正常甲状腺功能人群甲状腺激素水平与非酒精性脂肪肝的关系研究[J]. 中国全科医学, 2019, 22(25): 3088-3093. DOI: 10.12114/j.issn.1007-9572.2019.00.494.

References

［1］中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南［J］．中华肝脏病杂志，2010，18（3）：163-166．DOI：10.3760/cma.j.issn.1007-3418.2010.03.002.
National Workshop on Fatty Liver and Ahcololic Liver Disase，Chinese Society of Hepatology.Guidelines for management of non-alcoholic fatty liver disease：an updated and revised edition［J］．Chin J Hepatol，2010，18（3）：163-166．DOI：10.3760/cma.j.issn.1007-3418.2010.03.002.
［2］王丽莹，李强.血尿酸与非酒精性脂肪肝的相关性研究进展［J］．中国全科医学，2018，21（27）：3397-3402．DOI：10.3969/j.issn.1007-9572.2018.00.232．
WANG L Y，LI Q.Recent advances in the correlation between serum uric acid and nonalcoholic fatty liver disease［J］．Chin Gen Pract，2018，21（27）：3397-3402．DOI：10.3969/j.issn.1007-9572.2018.00.232．
［3］葛辉，陈君，孙毅明，等．广州市健康体检人群非酒精性脂肪肝患病情况及相关危险因素分析［J］．中华医学杂志，2016，96（46）：3706-3709．DOI：10.3760/ cma.j.issn.0376-2491.2016.46.003.
GE H，CHEN J，SUN Y M，et al．Prevalence of nonalcoholic fatty liver disease and its correlated risk factors in health population in Guangzhou［J］．Natl Med J China，2016，96（46）：3706-3709．DOI：10.3760/cma.j.issn.0376-2491.2016.46.003.
［4］PAGADALA M R，ZEIN C O，DASARATHY S，et al．Prevalence of hypothyroidism in nonalcoholic fatty liver disease［J］．Dig Dis Sci，2012，57（2）：528-534．DOI：10.1007/s10620-011-2006-2．
［5］MARTíNEZ ESCUDé A，PERA G，ARTEAGA I，et al．Relationship between hypothyroidism and non-alcoholic fatty liver disease in the Spanish population［J］．Med Clin（Barc），2019，153（2）：7-10．DOI：10.1016/j.medcli.2019.03.018.
［6］XU C F，XU L，YU C H，et al．Association between thyroid function and nonalcoholic fatty liver disease in euthyroid elderly Chinese［J］．Clin Endocrinol（Oxf），2011，75（2）：240-246．DOI：10.1111/j.1365-2265.2011.04016.x.
［7］LIU G L，ZHENG X，GUAN L Y，et al．Free triiodothyronine levels are positively associated with non-alcoholic fatty liver disease in euthyroid middle-aged subjects［J］．Endocr Res，2015，40（4）：188-193．DOI：10.3109/07435800.2014.987399.
［8］TAO Y，GU H B，WU J C，et al．Thyroid function is associated with non-alcoholic fatty liver disease in euthyroid subjects［J］．Endocr Res，2015，40（2）：74-78．DOI：10.3109/07435800.2014.952014.
［9］李嘉，郑瑾.2型糖尿病患者中性粒细胞/淋巴细胞与血糖控制水平相关性研究［J］．临床军医杂志，2017，45（5）：508-510，513．DOI：10.16680/j.1671-3826.2017.05.17.
LI J，ZHENG J.Association between neutrophil-lymphocyte ratio and blood glucose control level in patients with type 2 diabetes mellitus［J］．Clin J Med Off，2017，45（5）：508-510，513．DOI：10.16680/j.1671-3826.2017.05.17.
［10］杨光燃，袁申元，傅汉菁，等．颈围、腰围、腰臀比对2型糖尿病患者超重、肥胖及代谢综合征评价作用的比较研究［J］．中国全科医学，2016，19（7）：781-785．DOI：10.3969/j.issn.1007-9572.2016.07.009.
YANG G R，YUAN S Y，FU H J，et al．Function of neck circumference，waist circumference and waist-hip ratio in evaluating overweight，obesity and metabolic syndrome：a comparative study［J］．Chin Gen Pract，2016，19（7）：781-785．DOI：10.3969/j.issn.1007-9572.2016.07.009.
［11］中国高血压防治指南修订委员会．中国高血压防治指南2010［J］．中华心血管病杂志，2011，39（7）：579-616．DOI：10.3760/cma.j.issn.0253-3758.2011.07.002.
Writing Group of 2010 Chinese Guidelines for the Management of Hypertension．2010 Chinese guidelines for the management of hypertension［J］．Chin J Cardiol，2011，39（7）：579-616．DOI：10.3760/cma.j.issn.0253-3758.2011.07.002.
［12］冯颜，李静.甲状腺激素检测方法的研究进展［J］．临床内科杂志，2017，34（11）：791-792．DOI：10.3969/j.issn.1001-9057.2017.11.025.
FENG Y，LI J.Advances in thyroid hormone detection methods［J］．J Clin Intern Med，2017，34（11）：791-792．DOI：10.3969/j.issn.1001-9057.2017.11.025.
［13］ROEF G，LAPAUW B，GOEMAERE S，et al．Body composition and metabolic parameters are associated with variation in thyroid hormone levels among euthyroid young men［J］．Eur J Endocrinol，2012，167（5）：719-726．DOI：10.1530/EJE-12-0447.
［14］TARCIN O，ABANONU G B，YAZICI D，et al．Association of metabolic syndrome parameters with TT3 and FT3/FT4 ratio in obese Turkish population［J］．Metab Syndr Relat Disord，2012，10（2）：137-142．DOI：10.1089/met.2011.0098.

[1]	GE Dan, WANG Zhi, DING Qun, GUO Tonglan, XU Tongdao. Relationship between Remnant Cholesterol and Non-alcoholic Fatty Liver Disease as well as Progressive Liver Fibrosis in Patients with Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2026, 29(20): 2854-2859.
[2]	HUANG Minshan, CHEN Hang, LI Liya, YANG Taiming, CHEN Lifang, LI Shenchao, REN Li, WANG Hui, LI Mingke, WANG Xianmei, WANG Da, WAN Ying, HE Yule, ZHOU Qingqing, LI Yu, LI Mengwei, LU Lihong, LUO Yifan, MA Lanqing. The Current Status of Awareness and Influencing Factors Analysis of Metabolic-associated Fatty Liver Disease among the General Population in Multiple Regions of Yunnan [J]. Chinese General Practice, 2026, 29(17): 2347-2353.
[3]	LI Jie, YANG Xinhui, CAO Li, ZHANG Jing, JIANG Yue. Case Analysis of General Practice Diagnosis and Treatment in a "Three High" Patient with Coexistence and Fatty Liver Disease [J]. Chinese General Practice, 2026, 29(06): 810-816.
[4]	FAN Xueming, YANG Ningning, ZHENG Zheng, WU Yumei, WANG Qi. Analysis of Correlation Factors and Predictive Value of Microvascular Complications in Patients with Type 2 Diabetes Mellitus Combined with Metabolic-associated Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(36): 4578-4585.
[5]	YANG Bingqing, YANG Tianyuan, HOU Chenxue, WANG Qi. Comparative Study on the Potential of Non-invasive Models in Evaluating Liver Fibrosis in Patients with Chronic Hepatitis B Combined with Non-alcoholic Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(32): 4067-4074.
[6]	YANG Jian, WU Chuan'an, ZHOU Hairong, TIAN Feng, CHI Chunhua. Diagnostic Value of the Triglyceride Glucose-body Mass Index for Type 2 Diabetes Mellitus Combined with Metabolic Dysfunction-associated Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(32): 4075-4081.
[7]	ZHAO Yuqing, WANG Wei, CHEN Liyuan, YOU Huijuan, WEI Ying, WANG Qinglu, YANG Fengying. Liver Macrophage Polarisation: a New Target for Exercise Prevention and Treatment of Non-alcoholic Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(27): 3456-3465.
[8]	WU Sha, ZHANG Daiyi, LI Jin, XUAN Qinkao, QIAN Xiaodong, ZHU Chuanwu, PU Jianhong, ZHU Li. Correlation Analysis and Model Construction of Metabolic Associated Fatty Liver Disease and Hyperglycemia Based on a Health Examination Cohort [J]. Chinese General Practice, 2025, 28(23): 2861-2869.
[9]	LIU Yueying, WANG Xueli, LIU Yuqiu, WEI Limin. Correlation of Fasting C-peptide to Diabetes Duration Ration and Type 2 Diabetes Mellitus Combined with Metabolism-related Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(23): 2852-2860.
[10]	WANG Peng, QIU Lixia, XU Shanshan, ZHANG Yang, ZHANG Jing, DU Xiaofei. Advances in the Co-management of Metabolism Dysfunction-associated Fatty Liver Disease and Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2025, 28(23): 2846-2851.
[11]	BAI Xue, CHEN Qianqian, LI Jie. Innovative Practices in Chronic Disease Management: a New Model for Generalist-Specialist Combination Management of Diabetes and Metabolic Dysfunction-associated Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(23): 2841-2845.
[12]	ZHANG Quanai, LI Sha, WANG Kaiti, DONG Huicong, LU Xiaofei, GUO Yongze. Effect of Semaglutide in Hepatic Lipid Metabolism of Rats in a Methionine-choline Deficient Diet-induced Non-alcoholic Fatty Liver Disease Model [J]. Chinese General Practice, 2025, 28(20): 2538-2545.
[13]	NIE Yuanyuan, FANG Da, XU Hao, YANG Donghui, BI Yan, GU Tianwei. Clinical Characteristics and Cardiovascular Disease Risk of Type 2 Diabetes Populations with Different Liver Fibrosis Risks [J]. Chinese General Practice, 2025, 28(15): 1847-1854.
[14]	NI Xuetong, AHEYEERKE Halengbieke, TANG Jianmin, CAO Tengrui, TAO Lixin, ZHENG Deqiang, LI Qiang, HAN Yumei, YANG Xinghua. The Bidirectional Temporal Causal Association Study between Dysglycaemia and Non-alcoholic Fatty Liver Disease: Based on the Beijing Health Management Cohort [J]. Chinese General Practice, 2025, 28(13): 1607-1613.
[15]	ZHUO Lili, QU Huanjia, ZHANG Qiuling. The Effect of Type 2 Diabetes Mellitus and Obesity on FIB-4 Index Screening for Early Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(11): 1354-1360.